Multi-planner validation of RapidPlan knowledge-based model for volumetric modulated arc therapy in prostate cancer.

PURPOSE: To investigate the performance of a model-based optimization process for volumetric modulated arc therapy (VMAT) applied to prostate cancer patients with the multi-planner. METHODS AND MATERIALS: The 120 prostate plans for VMAT treatment were entered into the database system of the RapidPlan (RP) knowledge-based treatment planning. The treatment planning data for each plan was used to create and train the RP model. Twelve prostate cancer cases were selected and were used for planning by a manual of 12 planners based on the clinical protocol for dose constraints. Then, the treatment plans for each patient were compared with the RP model plans and analyzed with Wilcoxon tests. RESULTS: On average, the RP models can estimate comparable doses among all planner plans and clinical plans for the PTV, which Dmax , D95% , D98% , HI, and CI were used to evaluate. For the normal organ doses of the bladder, rectum, penile bulb, and femoral head, all RP model plans showed comparable or better dose sparing than all planner plans and clinical plans. Moreover, the average planning time of the RP model was faster than manual plans by about two times. The RP model can significantly reduce the variation dose of the normal organs compared with the manual plans among the planners. CONCLUSION: The automated plans of the RP model might benefit from further fine-tuning of the dose constraints of the normal organs, although both procedure plans are acceptable and fulfill the clinical protocol goals so that the RP model can enhance the efficacy and quality of plans.

Epigallocatechin-3-Gallate Protects Pro-Acinar Epithelia Against Salivary Gland Radiation Injury.

Antioxidant agents are promising pharmaceuticals to prevent salivary gland (SG) epithelial injury from radiotherapy and their associated irreversible dry mouth symptoms. Epigallocatechin-3-gallate (EGCG) is a well-known antioxidant that can exert growth or inhibitory biological effects in normal or pathological tissues leading to disease prevention. The effects of EGCG in the various SG epithelial compartments are poorly understood during homeostasis and upon radiation (IR) injury. This study aims to: (1) determine whether EGCG can support epithelial proliferation during homeostasis; and (2) investigate what epithelial cells are protected by EGCG from IR injury. Ex vivo mouse SG were treated with EGCG from 7.5-30 µg/mL for up to 72 h. Next, SG epithelial branching morphogenesis was evaluated by bright-field microscopy, immunofluorescence, and gene expression arrays. To establish IR injury models, linear accelerator (LINAC) technologies were utilized, and radiation doses optimized. EGCG epithelial effects in these injury models were assessed using light, confocal and electron microscopy, the Griess assay, immunohistochemistry, and gene arrays. SG pretreated with EGCG 7.5 µg/mL promoted epithelial proliferation and the development of pro-acinar buds and ducts in regular homeostasis. Furthermore, EGCG increased the populations of epithelial progenitors in buds and ducts and pro-acinar cells, most probably due to its observed antioxidant activity after IR injury, which prevented epithelial apoptosis. Future studies will assess the potential for nanocarriers to increase the oral bioavailability of EGCG.

The impact of corrected field output factors based on IAEA/AAPM code of practice on small-field dosimetry to the calculated monitor unit in eclipse™ treatment planning system.

The objective of this study was to investigate the effect of field output factors (FOFs) according to the current protocol for small-field dosimetry in conjunction to treatment planning system (TPS) commissioning. The calculated monitor unit (MU) for intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) plans in Eclipse™ TPS were observed. Micro ion chamber (0.01 CC) (CC01), photon field diode (shielded diode) (PFD), and electron field diode (unshielded diode) (EFD) were used to measure percentage depth doses, beam profiles, and FOFs from 1 × 1 cm2 to 10 × 10 cm2 field sizes of 6 MV photon beams. CC01 illustrated the highest percentage depth doses at 10 cm depth while EFD exhibited the lowest with the difference of 1.6% at 1 × 1 cm2 . CC01 also produced slightly broader penumbra, the difference with other detectors was within 1 mm. For uncorrected FOF of three detectors, the maximum percent standard deviation (%SD) was 5.4% at 1 × 1 cm2 field size. When the correction factors were applied, this value dropped to 2.7%. For the calculated MU in symmetric field sizes, beam commissioning group from uncorrected FOF demonstrated maximum %SD of 6.0% at 1 × 1 cm2 field size. This value decreased to 2.2% when the corrected FOF was integrated. For the calculated MU in IMRT-SRS plans, the impact of corrected FOF reduced the maximum %SD from 6.0% to 2.5% in planning target volume (PTV) less than 0.5 cm3 . Beam commissioning using corrected FOF also decreased %SD for VMAT-SRS plans, although it was less pronounced in comparison to other treatment planning techniques, since the %SD remained less than 2%. The use of FOFs based on IAEA/AAPM TRS 483 has been proven in this research to reduce the discrepancy of calculated MU among three beam commissioning datasets in Eclipse™ TPS. The dose measurement of both symmetric field and clinical cases comparing to the calculation illustrated the dependence of the types of detector commissioning and the algorithm of the treatment planning for small field size.

Effectiveness of multi-criteria optimization in combination with knowledge-based modeling in radiotherapy of left-sided breast including regional nodes.

Multi-criteria optimization (MCO) is a method that was added to treatment planning to create high-quality treatment plans. This study aimed to investigate the effectiveness of MCO in combination with knowledge-based planning (KBP) in radiotherapy for left-sided breasts, including regional nodes. Dose/volume parameters were evaluated for manual plans (MP), KBP, and KBP + MCO. Planning target volume doses of MP had better coverage while KBP + MCO plans demonstrated the lowest organ at risk doses. KBP and KBP + MCO plans had increasing complexity as expressed in the number of monitor units.

Multimodality radiomics for tumor prognosis in nasopharyngeal carcinoma.

BACKGROUND: The prognosis of nasopharyngeal carcinoma (NPC) is challenging due to late-stage identification and frequently undetectable Epstein-Barr virus (EBV) DNA. Incorporating radiomic features, which quantify tumor characteristics from imaging, may enhance prognosis assessment. PURPOSE: To investigate the predictive power of radiomic features on overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) in NPC. MATERIALS AND METHODS: A retrospective analysis of 183 NPC patients treated with chemoradiotherapy from 2010 to 2019 was conducted. All patients were followed for at least three years. The pretreatment CT images with contrast medium, MR images (T1W and T2W), as well as gross tumor volume (GTV) contours, were used to extract radiomic features using PyRadiomics v.2.0. Robust and efficient radiomic features were chosen using the intraclass correlation test and univariate Cox proportional hazard regression analysis. They were then combined with clinical data including age, gender, tumor stage, and EBV DNA level for prognostic evaluation using Cox proportional hazard regression models with recursive feature elimination (RFE) and were optimized using 20 repetitions of a five-fold cross-validation scheme. RESULTS: Integrating radiomics with clinical data significantly enhanced the predictive power, yielding a C-index of 0.788 ± 0.066 to 0.848 ± 0.079 for the combined model versus 0.745 ± 0.082 to 0.766 ± 0.083 for clinical data alone (p<0.05). Multimodality radiomics combined with clinical data offered the highest performance. Despite the absence of EBV DNA, radiomics integration significantly improved survival predictions (C-index ranging from 0.770 ± 0.070 to 0.831 ± 0.083 in combined model versus 0.727 ± 0.084 to 0.734 ± 0.088 in clinical model, p<0.05). CONCLUSIONS: The combination of multimodality radiomic features from CT and MR images could offer superior predictive performance for OS, PFS, and DMFS compared to relying on conventional clinical data alone.

Patient-Specific Quality Assurance in Pencil Beam Scanning by 2-Dimensional Array.

Purpose: This study aimed to determine the characteristics of 2D ionization chamber array and the confidence limits of the gamma passing rate in pencil beam scanning proton therapy. Materials and Methods: The Varian ProBeam Compact spot-scanning system and the PTW OCTAVIUS 1500XDR array were used as a proton therapy system and detector, respectively. Our methods consisted of 2 parts: (1) the characteristics of the detector were tested and (2) patient-specific quality assurance was performed and evaluated by gamma analysis using dose-difference and distance-to-agreement criteria of 3% and 2 mm, respectively, with 123 treatment plans in head and neck, breast, chest, abdomen, and pelvic regions. Results: The PTW OCTAVIUS 1500XDR array had good reproducibility, uniformity, linearity, repetition rate, and monitor unit per spot within 0.1%, with accuracy, energy dependence, and measurement depth within 0.5%. The overall uncertainty of the PTW OCTAVIUS 1500XDR array was 2.49%. For field size and range shifter, using gamma analysis, the passing rate was 100%. The overall results of patient-specific quality assurance with the gamma evaluation were 98.9% ± 1.6% in 123 plans and confidence limit was 95.7%. Conclusion: The PTW OTAVIUS 1500XDR offered effective performance in pencil beam scanning proton therapy.

Dosimetric Characteristics of Radiophotoluminescent Glass Dosimeters for Proton Beams.

Purpose: The purpose of the study was to investigate the dosimetric characteristics of radiophotoluminescent glass dosimeters (RGDs) for pencil beam scanning proton therapy. The RGD's end-to-end testing of intensity-modulated proton therapy (IMPT) plans was also evaluated. Materials and Methods: The dosimetric characteristics of the GD-302M type glass dosimeter were studied in terms of uniformity, short-term and long-term reproducibility, stability of the magazine position readout, dose linearity in the range from 0.2 to 20 Gy, energy response in 70-220 MeV, and fading effect. The reference conditions of the spot scanning beam from the Varian ProBeam Compact system were operation at 160 MeV, a 2 cm water-equivalent depth in a solid water phantom, a 10 cm × 10 cm field size at the isocenter, and 2 Gy dose delivery. End-to-end testing of IMPT plans for the head, abdomen, and pelvis was verified using the Alderson Rando phantom. The overall uncertainty analysis was confirmed in this study. Results: The relative response of RGDs for the uniformity test was within 0.95-1.05. The percentages of the coefficients of variation for short-term and long-term reproducibility were 1.16% and 1.50%, respectively. The dose ACE glass dosimetry reader FGD-1000 showed a stable magazine position readout. The dose was found to be linear with R2 = 0.9988. The energy response relative to 160 MeV was approximately within 4.0%. The fading effect was within 2.4%. For the end-to-end test, the difference between the treatment plan and RGD measurement was within 1.0%. The overall uncertainty of the RGD measurement for the proton beam was 4.6%, which covered all energy ranges in this study. Conclusion: The experimental study indicates that the RGDs have the potential to be used in the dosimetry of therapeutic proton beams, including end-to-end dosimetry.

Validation of the Fabricated Cast Nylon Head Phantom for Stereotactic Radiosurgery End-to-End Test using Alanine Dosimeter.

Background: Stereotactic radiosurgery (SRS) is an alternative to surgery as it precisely delivers single-large doses to small tumors. Cast nylon is used in phantom due to its computed tomography (CT) number of about 56-95 HU, which is close to that of the soft tissue. Moreover, cast nylon is also more budget-friendly than the commercial phantoms. Aims: The aim of this study is to design and validate the fabricated cast nylon head phantom for SRS end-to-end test using an alanine dosimeter. Materials and Methods: The phantom was designed using cast nylon. It was initially created by a computer numerical control three-axis vertical machining center. Then, the cast nylon phantom was scanned using a CT simulator. Finally, the validation of the fabricated phantom using alanine dosimeter proficiency with four Varian LINAC machines was performed. Results: The fabricated phantom presented a CT number of 85-90 HU. The outcomes of VMAT SRS plans showed percentage dose differences from 0.24 to 1.55, whereas the percentage dose differences in organ at risk (OAR) were 0.09-10.80 due to the low-dose region. The distance between the target (position 2) and the brainstem (position 3) was 0.88 cm. Conclusions: Variation in dose for OAR is higher, which might be due to a high-dose gradient in the area where measurement was being conducted. The fabricated cast nylon end-to-end test head phantom had been suitably designed to image and irradiate during an end-to-end test for SRS using an alanine dosimeter.

Assessment of the Dosimetric Performance of the Mobius3D against Portal Dose Measurements in Patient-specific Quality Assurance.

Aim: The Mobius3D software addresses limitations lacking in measurement-based methods in patient-specific quality assurance (QA). The objective of this study was to validate its dosimetric performance against conventionally used portal dose measurements using gamma analysis and confidence limits. Materials and Methods: A total of 240 patient-specific QA plans for the Varian Halcyon linear accelerator were collected. The Mobius3D software was commissioned through beam data and plan verification. All plans underwent QA through the electronic portal imaging device, coupled with the Portal Dosimetry software, and the Mobius3D. Data were assessed using >95% gamma pass. Portal measurements were evaluated using 3%/2 mm and 3%/3 mm criteria, whereas Mobius3D was analyzed at 3%/3 mm and 5%/3 mm, at the 10% threshold. Results: Mobius 5%/3 mm mean gamma passes were 99.89% for volumetric-modulated arc therapy (VMAT) and 99.31% for intensity-modulated radiotherapy (IMRT), and correspondingly, the data for portal 3%/2 mm were 99.99% and 99.96%. The Mobius3D at 5%/3 mm can perform like Portal 3%/2 mm for VMAT plans at 0.1% difference, especially for head/neck and pelvic/abdominal cases. In IMRT-based treatments, at 0.7% difference in Mobius3D 5%/3 mm and Portal 3%/2 mm, the performance and error identification in IMRT plans should be applied more carefully due to the amount of failed plans, particularly the chest region. The confidence limits for VMAT plans for Portal 3%/2 mm and Mobius 5%/3 mm are 99.93% and 99.42%, respectively, while for IMRT plans are 99.69% and 97.43%, respectively. Conclusions: At a 5%/3 mm criterion, the Mobius3D may yield percentage gamma pass rates like measurements obtained by Portal Dosimetry 3%/3 mm and Portal Dosimetry 3%/2 mm. As the software is largely dependent on commissioned data, rigorous commissioning and a comprehensive QA program should be implemented.

Improved prediction of radiation-induced hypothyroidism in nasopharyngeal carcinoma using pre-treatment CT radiomics.

When planning radiation therapy, late effects due to the treatment should be considered. One of the most common complications of head and neck radiation therapy is hypothyroidism. Although clinical and dosimetric data are routinely used to assess the risk of hypothyroidism after radiation, the outcome is still unsatisfactory. Medical imaging can provide additional information that improves the prediction of hypothyroidism. In this study, pre-treatment computed tomography (CT) radiomics features of the thyroid gland were combined with clinical and dosimetric data from 220 participants to predict the occurrence of hypothyroidism within 2 years after radiation therapy. The findings demonstrated that the addition of CT radiomics consistently and significantly improves upon conventional model, achieving the highest area under the receiver operating characteristic curve (AUCs) of 0.81 ± 0.06 with a random forest model. Hence, pre-treatment thyroid CT imaging provides useful information that have the potential to improve the ability to predict hypothyroidism after nasopharyngeal radiation therapy.

Determination of Integral Depth Dose in Proton Pencil Beam Using Plane-parallel Ionization Chambers.

Purpose: This study aimed to determine the integral depth-dose curves and assess the geometric collection efficiency of different detector diameters in proton pencil beam scanning. Materials and Methods: The Varian ProBeam Compact spot scanning system was used for this study. The integral depth-dose curves with a proton energy range of 130 to 220 MeV were acquired with 2 types of Bragg peak chambers: 34070 with 8-cm diameter and 34089 with 15-cm diameter (PTW), multi-layer ionization chamber with 12-cm diameter (Giraffe, IBA Dosimetry), and PeakFinder with 8-cm diameter (PTW). To assess geometric collection efficiency, the integral depth-dose curves of 8- and 12-cm chamber diameters were compared to a 15-cm chamber diameter as the largest detector. Results: At intermediate depths of 130, 150, 190, and 220 MeV, PTW Bragg peak chamber type 34089 provided the highest integral depth-dose curves followed by IBA Giraffe, PTW Bragg peak chamber type 34070, and PTW PeakFinder. Moreover, PTW Bragg peak chamber type 34089 had increased geometric collection efficiency up to 3.8%, 6.1%, and 3.1% when compared to PTW Bragg peak chamber type 34070, PTW PeakFinder, and IBA Giraffe, respectively. Conclusion: A larger plane-parallel ionization chamber could increase the geometric collection efficiency of the detector, especially at intermediate depths and high-energy proton beams.

Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer.

Background and purpose: Specific proton-beam configurations are needed to spare organs at risk (OARs), including lungs, heart, and spinal cord, when treating esophageal squamous cell carcinoma (ESCC) in the thoracic region. This study aimed to propose new intensity-modulated proton therapy (IMPT) beam configurations and to demonstrate the benefit of IMPT compared with intensity-modulated x-ray therapy (IMXT) for treating ESCC. Material and methods: IMPT plans with three different beam angle configurations were generated on CT datasets of 25 ESCC patients that were treated with IMXT. The IMPT beam designs were two commonly-used beam configurations (anteroposterior and posterior oblique) and a recently proposed beam configuration (anterosuperior with posteroinferior). The target doses were 50-54 Gy(RBE) and 60-64 Gy(RBE) to the low-risk and high-risk target volumes, respectively. Robust optimization was applied for the IMPT plans. The differences in the dose-volume parameters between the IMXT and IMPT plans were compared. Results: With target coverage comparable to standard IMXT, IMPT had significantly lower mean doses to the OARs. IMPT with an anteroposterior opposing beam generated the lowest lung dose (mean = 7.1 Gy(RBE), V20 = 14.1%) and the anterosuperior with posteroinferior beam resulted in the lowest heart dose (mean = 12.8 Gy(RBE), V30 = 15.7%) and liver dose (mean = 3.9 Gy(RBE), V30 = 5.9%). For the subgroup of patients with an inferior tumor location (PTVs overlapping a part of the contoured heart), the novel beam demonstrated the optimal OARs sparing. Conclusion: Compared with IMXT, the IMPT plans significantly reduced the radiation dose to the surrounding organs when treating ESCC. IMPT beam configuration selection depends on the tumor location relative to the heart.

Tumor Prognostic Prediction of Nasopharyngeal Carcinoma Using CT-Based Radiomics in Non-Chinese Patients.

PURPOSE: We aimed to construct predictive models for the overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) for nasopharyngeal carcinoma (NPC) patients by using CT-based radiomics. MATERIALS AND METHODS: We collected data from 197 NPC patients. For each patient, radiomic features were extracted from the CT image acquired at pretreatment via PyRadiomics. Feature selection was performed in two steps. First, features with high inter-observer variability based on multiple tumor delineations were excluded. Then, stratified bootstrappings were performed to identify feature combinations that most frequently achieved the highest (i) area under the receiver operating characteristic curve (AUC) for predicting 3-year OS, PFS, and DMFS or (ii) Harrell's C-index for predicting time to event. Finally, regularized logistic regression and Cox proportional hazard models with the most frequently selected feature combinations as input were tuned using cross-validation. Additionally, we examined the robustness of the constructed model to variation in tumor delineation by simulating 100 realizations of radiomic feature values to mimic features extracted from different tumor boundaries. RESULTS: The combined model that used both radiomics and clinical features yielded significantly higher AUC and Harrell's C-index than models using either feature set alone for all outcomes (p < 0.05). The AUCs and Harrell's C-indices of the clinical-only and radiomics-only models ranged from 0.758 ± 0.091 to 0.789 ± 0.082 and from 0.747 ± 0.062 to 0.767 ± 0.074, respectively. In comparison, the combined models achieved AUC of 0.801 ± 0.075 to 0.813 ± 0.078 and Harrell's C-indices of 0.779 ± 0.066 to 0.796 ± 0.069. The results showed that our models were robust to variation in tumor delineation with the coefficient of variation ranging from 4.8% to 6.4% and from 6.7% to 9.3% for AUC and Harrell's C-index, respectively. CONCLUSION: Our results demonstrated that using CT-based radiomic features together with clinical features provided superior NPC prognostic prediction than using either clinical or radiomic features alone.

High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.

BACKGROUND: Chemoradiotherapy is the standard of care for esophageal cancer as a neoadjuvant treatment before surgery, or as a definitive treatment for unresectable disease. Intensity-modulated radiotherapy (IMRT) has been considered the standard radiation technique. However, patients suffer from treatment-related toxicities, and most die from disease progression or recurrence. With emerging technological advancement, proton therapy has theoretical advantages over IMRT because it offers apparent dosimetric benefits to allow dose escalation to the target while better sparing surrounding tissues such as the lungs, heart, liver, and spinal cord. The purpose of this study protocol is to investigate the survival benefit of proton therapy using modern intensity-modulated proton therapy (IMPT) compared to standard IMRT for esophageal cancer. METHODS: This is a two-arm open phase II/III multi-institution randomized controlled trial. Eligible patients will have histologically confirmed squamous cell carcinoma of the thoracic esophagus with no evidence of tracheoesophageal/esophagobronchial fistula or distant metastasis. After stratification according to resectability status (resectable vs. borderline resectable/unresectable), a total of 232 patients will be randomized to receive IMPT or IMRT using a 1:1 allocation ratio. In resectable cases, surgical resection following concurrent chemoradiation will be attempted for the patients who are medically fit at the time of surgery. In those with initially borderline resectable/unresectable disease, definitive concurrent chemoradiation will be performed. The phase II study will assess safety (toxicity and postoperative complications) and feasibility (recruitment rate and chemoradiation dose modification) in 40 patients into each arm. The study will then continue into phase III, further recruit 76 patients into each arm, and compare progression-free survival between IMPT vs IMRT groups. The secondary endpoints will be overall survival, local and distant control, toxicities, health-related quality of life, and cost-utility. This protocol describes a detailed radiotherapy and chemotherapy. DISCUSSION: This randomized clinical trial will demonstrate the clinical benefit of IMPT in esophageal cancer treatment in terms of survival and toxicity outcomes which will further establish high-level evidence for radiation modality in squamous cell carcinoma of the thoracic esophagus. TRIAL REGISTRATION: TCTR20200310006 . Registered 10 March 2020.

Determination of field output correction factors of radiophotoluminescence glass dosimeter and CC01 ionization chamber and validation against IAEA-AAPM TRS-483 code of practice.

PURPOSE: To determine the field output correction factors of the radiophotoluminescence glass dosimeter (RPLGD) in parallel and perpendicular orientations with reference to CC01, the ionization chamber. METHODS: The dose to a small water volume and the sensitive volume of the RPLGD and the IBA-CC01 were determined for 6-MV, 100-cm SAD, 10-cm depth using egs_chamber user-code. The RPLGD in perpendicular and parallel orientations to the beam axis were studied. The field output correction factors of each detector for 0.5 × 0.5 to 10 × 10 cm2 field sizes were determined. These field output correction factors were validated by comparing field output factors against data determined from IAEA-AAPM TRS-483 code of practice. RESULTS: The field output correction factors of all detectors were within 5% for field sizes down to 0.8 × 0.8 cm2. For 0.5 × 0.5 cm2, the field output correction factors of CC01, RPLGD in perpendicular and parallel orientations differed from unity by 14%, 19%, and 5%, respectively. The percentage difference between field output factors determined using RPLGD and CC01 data, corrected using the field output correction factors determined in this work and measurements with CC01 data corrected using TRS-483, was less than 3% for all field sizes, except for the smallest field size of RPLGD in perpendicular orientation and the CC01. CONCLUSIONS: The field output correction factors of RPLGD and CC01 are reported. The validation proves that RPLGD in parallel orientation combined with the field output correction factors is the most suitable for determining the field output factors for the smallest field used in this study.

LINE-1 methylation status of endogenous DNA double-strand breaks.

DNA methylation and the repair of DNA double-strand breaks (DSBs) are important processes for maintaining genomic integrity. Although DSBs can be produced by numerous agents, they also occur spontaneously as endogenous DSBs (EDSBs). In this study, we evaluated the methylation status of EDSBs to determine if there is a connection between DNA methylation and EDSBs. We utilized interspersed repetitive sequence polymerase chain reaction (PCR), ligation-mediated PCR and combined bisulfite restriction analysis to examine the extent of EDSBs and methylation at long interspersed nuclear element-1 (LINE-1) sequences nearby EDSBs. We tested normal white blood cells and several cell lines derived from epithelial cancers and leukemias. Significant levels of EDSBs were detectable in all cell types. EDSBs were also found in both replicating and non-replicating cells. We found that EDSBs contain higher levels of methylation than the cellular genome. This hypermethylation is replication independent and the methylation was present in the genome at the location prior to the DNA DSB. The differences in methylation levels between EDSBs and the rest of the genome suggests that EDSBs are differentially processed, by production, end-modification, or repair, depending on the DNA methylation status.

Determination of radiation dose and low-dose protocol for digital chest tomosynthesis using radiophotoluminescent (RPL) glass dosimeters.

PURPOSE: This study aimed to determine a low-dose protocol for digital chest tomosynthesis (DTS). METHODS: Five simulated nodules with a CT number of approximately 100 HU with size diameter of 3, 5, 8, 10, and 12 mm were inserted into an anthropomorphic chest phantom (N1 Lungman model), and then scanned by DTS system (Definium 8000) with varying tube voltage, copper filter thickness, and dose ratio. Three radiophotoluminescent (RPL) glass dosimeters, type GD-352 M with a dimension of 1.5 × 12 mm, were used to measure the entrance surface air kerma (ESAK) in each protocol. The effective dose (ED) was calculated using the recorded total dose-area-product (DAP). The signal-to-noise ratio (SNR) was determined for qualitative image quality evaluation. The image criteria and nodule detection capability were scored by two experienced radiologists. The selected low-dose protocol was further applied in a clinical study with 30 pulmonary nodule follow-up patients. RESULTS: The average ESAK obtained from the standard default protocol was 1.68 ± 0.15 mGy, while an ESAK of 0.47 ± 0.02 mGy was found for a low-dose protocol. The EDs for the default and low-dose protocols were 313.98 ± 0.72 µSv and 100.55 ± 0.28 µSv, respectively. There were small non-significant differences in the image criteria and nodule detection scoring between the low-dose and default protocols interpreted by two radiologists. The effective dose of 98.87 ± 0.08 µSv was obtained in clinical study after applying the low-dose protocol. CONCLUSIONS: The low-dose protocol obtained in this study can substantially reduce radiation dose while preserving an acceptable image quality compared to the standard protocol.

Dosimetric study of inverse-planed intensity modulated, forward-planned intensity modulated and conventional tangential techniques in breast conserving radiotherapy.

OBJECTIVE: The authors present the result of a dosimetric comparison of inverse-planed intensity modulated, forward-planned intensity modulated, and conventional tangential technique in breast conserving radiotherapy. METHOD AND MATERIAL: The breasts (Right side: Left side = 1:1), heart, and lungs of 28 patients were contoured on all the computed tomography (CT)-slice. Three different treatment plans were created: (1) inverse IMRT (iIMRT), (2) forward IMRT (fIMRT), and (3) conventional tangential technique (CVT). The total prescribed dose for all plans was 50 Gy/25 fractions. All treatment plans were normalized at 95% of the prescribed dose covered the entire PTV and used inhomogeneity corrections. RESULTS: For the entire group, the mean breast volume was 517 cc. The V105% for iIMRT, fIMRT and conventional plans was 1.12%, 2.36% and 16.81%, which iIMRT better than fIMRT and CVT (p < 0.001) and fIMRT better than CVT (p < 0.05). The Dmax for the iIMRT plan received 105.03%, which was significantly less than those from the fIMRT(106.6%, p < 0.001) and the conventional (110.68%, p < 0.001) plan. The PTV coverage (V95-105%) for the iIMRT, fIMRTand conventional was 96%, 91% and 87%, which iIMRT better than fIMRT and CVT (p < 0.05) and fIMRT better than CVT (p < 0.05). The PTV CI for the iIMRT technique was 0.704, which was significantly more conformity than those from the fIMRT (0.639, p < 0.001) and the conventional (0.539, p < 0.001) techniques. The PTV CI of fIMRT is significantly better than CVT (p < 0.005). Mean ipsilateral lung dose was 642.7 cGy, 747.6 cGy and 882.25 cGy for iIMRT fIMRT and CVT respectively (p < 0.05) The V20Gy reduced from 14.87% for conventional plan to 12.82% for the fIMRT plan, while 0.88% was obtained for the iIMRT plan (P<0.05). The heart V30 Gy value was 3.124%, 4.65%, and 5.84% for iIMRT, fIMRT and conventional plans, respectively (p < 0.05). The mean dose of contralateral breast was 55.86 cGy, 60.33 cGy, 68.57 cGy for iIMRT, fIMRT and conventional plans, respectively (p < 0.05 both). The mean contralateral lung dose was 57.8 cGy, 43.87 cGy, and 32.28 cGy for iIMRT, fIMRT and conventional plans, respectively (p < 0.005 both). CONCLUSION: The iIMRT technique provides significantly improved PTV Dmax, PTV V105%, PTV V110%, target volume coverage, dose homogeneity and dose conformity throughout the target volume of breast and reduced doses to all critical structures, compared to the fIMRT and conventional techniques. In view of fIMRT technique, it significantly improved the dose distribution and reduced dose to OARs compared to conventional technique, although not better than iIMRT technique.

A two-year experience of implementing 3 dimensional radiation therapy and intensity-modulated radiation therapy for 925 patients in King Chulalongkorn Memorial Hospital.

BACKGROUND AND OBJECTIVE: Three dimensional conformal radiation therapy (3D CRT) and intensity-modulated radiation therapy (IMRT) have been implemented at Department of Therapeutic Radiation and Oncology, King Chulalongkorn Memorial Hospital (KCMH) since July 2005. This is the first study in Thailand to evaluate the pattern of care and utilization of 3D CRT and IMRT for treatment in each individual cancer. MATERIAL AND METHOD: Between July 2005 and July 2007, 925 newly diagnosed cancer patients underwent IMRT or 3D CRT at KCMH. The authors retrospectively reviewed the experience and utilization of 3D CRT and IMRT for each disease site and region. RESULTS: There were 471 males and 454 females. There were 332 patients (35.9%) treated with IMRT. Among the 332 IMRT patients, there were 100, 32 and 27 nasopharyngeal, lung and prostate cancers, respectively. On the contrary, 593 patients (64.1%) were treated with 3D CRT. Among these, breast, cervix and lung cancers were the most common diseases. Except for head and neck as well as genitourinary cancer 3D CRT was still the main technique used in more than 60% of the patients at KCMH. CONCLUSION: 3D CRT and IMRT have been successfully implemented at KCMH for 2 years. Three dimensional conformal radiation therapy was still the main technique used in more than 60% of the patients at KCMH. Prospective studies evaluating tumor control and treatment sequelae are expected.

Radiation dose to medical staff in interventional radiology.

OBJECTIVE: The purposes of the present study were to determine the dose to medical staff in interventional radiology at different locations on the body measured by thermoluminescent dosimeter (TLD) and to relate the medical staff dose to patient dose measured by the dose-area product (DAP) meter. MATERIAL AND METHOD: The present study covered 42 patients in three interventional radiology procedures with three x-ray machines. Thermoluminescent dosimeters were stuck at eight positions on the radiologist's skin during the procedure. In addition, direct reading from the DAP meter placed in front of the collimator of the x-ray tube, was recorded to estimate the patient radiation dose. RESULTS: The surface dose to the primary radiologist showed maximum value at the left forearm of 407 microGy. The ratios between the maximum interventional radiologist surface dose and patient dose are 12.88 microGy per 10 Gycm2 for transarterial oily chemoembolization TOCE (Siemens Polystar), 22.58 microGy per 10 Gycm2 for transarterial oily chemoembolization TOCE (Siemens Neurostar), 148.29 microGy per 10 Gycm2 for percutaneous transhepatic biliary drainage PTBD (Siemens Polystar) and 100.46 microGy per 10 Gycm2for endoscopic retrograde cholangiopancreatography ERCP (GE Advantx). CONCLUSION: The interventional radiologist surface dose can be estimated from the mentioned ratio if the patient dose is measured. This will help the radiologists to avoid receiving an excess dose during their work.